The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BOPA 2017 | Analyzing the affordability of additional multiple myeloma drugs
Affordable treatment reduces the burden on the healthcare services and increases the chances of NICE approval. Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Ms Man-Chie Chow from the Royal Surrey County Hospital, Guildford, UK discusses how NICE may assess new treatments alongside lenalidomide for multiple myeloma, and provides an overview of the methods that pharmaceutical companies can use to make new treatments more affordable whilst adhering to ABPI rules.
